Kensington Investment Counsel’s Vertex Pharmaceuticals VRTX Stock Holding History

Kensington Investment Counsel’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$745K	Sell	1,500 -53	-3%	-$23.5K	0.32%	59
2026 Q1	$693K	Sell	1,553 -21	-1%	-$9.79K	0.33%	57
2025 Q4	$714K	Buy	1,574 +48	+3%	+$20.7K	0.29%	75
2025 Q3	$598K	Buy	1,526 +23	+2%	+$9.61K	0.24%	78
2025 Q2	$669K	Buy	1,503 +7	+0.5%	+$3.23K	0.29%	72
2025 Q1	$725K	Sell	1,496 -60	-4%	-$28K	0.32%	72
2024 Q4	$627K	Sell	1,556 -97	-6%	-$45K	0.26%	79
2024 Q3	$769K	Hold	1,653	–	–	0.32%	78
2024 Q2	$775K	Buy	1,653 +5	+0.3%	+$2.17K	0.34%	76
2024 Q1	$689K	Buy	+1,648	New	+$697K	0.31%	80

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Kensington Investment Counsel's VRTX Position: Q2 2026 in Review

Kensington Investment Counsel reduced its Vertex Pharmaceuticals (VRTX) stake by 3.4% in Q2 2026, selling an estimated $23.5K and leaving 1,500 shares worth $745K. The position accounts for 0.32% of the portfolio, ranked #59.

Kensington Investment Counsel first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $775K in Q2 2024. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Kensington Investment Counsel held 1,500 shares of Vertex Pharmaceuticals worth $745K as of Q2 2026.
Kensington Investment Counsel sold 53 Vertex Pharmaceuticals shares in Q2 2026, an estimated $23.5K.
Vertex Pharmaceuticals made up 0.32% of Kensington Investment Counsel's portfolio in Q2 2026, its #59 holding.
Kensington Investment Counsel first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Kensington Investment Counsel's Vertex Pharmaceuticals position peaked at $775K in Q2 2024.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Kensington Investment Counsel's 13F filing for Q2 2026, filed 14 Aug 2026.